









市场行情
/
股票
/
nasdaq-atha
/

Athira Pharma Inc

ATHA

6.970USD

+0.250+3.72%

收盘 12/19, 16:00（美东）报价延迟15分钟

27.49M总市值

亏损市盈率 TTM



Athira Pharma Inc

6.970

+0.250+3.72%

概览公司财务分析

概览

公司

财务

分析

关于 Athira Pharma Inc 公司

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

Athira Pharma Inc简介



公司代码ATHA

公司名称Athira Pharma Inc

上市日期Sep 18, 2020

CEOLitton (Mark James)

员工数量26

证券类型Ordinary Share

年结日Sep 18

公司地址18706 North Creek Parkway, Suite 104

城市BOTHELL

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编98011

电话14256208501

网址https://www.athira.com/

公司代码ATHA

上市日期Sep 18, 2020

CEOLitton (Mark James)

Athira Pharma Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Mark James Litton, Ph.D.

President, Chief Executive Officer, Director

34.55K

-6.78%

Dr. Kevin Church, Ph.D.

Chief Scientific Officer

16.89K

-4.81%

Mr. Mark Worthington

Chief Compliance Officer, General Counsel, Company Secretary

11.19K

-7.08%

Mr. Robert Renninger

Senior Vice President - Finance, Accounting

10.92K

-2.59%

Ms. Kelly A. Romano

Independent Chairwoman of the Board

8.07K

-23.06%

Dr. Javier San Martin, M.D.

Chief Medical Officer

7.17K

-13.14%

Mr. Grant E. Pickering

Independent Director

2.58K

James A. Johnson ,

Independent Director

500.00

Ms. Barbara Kosacz, J.D.

Independent Director

Ms. Julie Rathbun

Investor Relations

名称

名称/职务

职务

持股

持股变动

Dr. Mark James Litton, Ph.D.

President, Chief Executive Officer, Director

34.55K

-6.78%

Dr. Kevin Church, Ph.D.

Chief Scientific Officer

16.89K

-4.81%

Mr. Mark Worthington

Chief Compliance Officer, General Counsel, Company Secretary

11.19K

-7.08%

Mr. Robert Renninger

Senior Vice President - Finance, Accounting

10.92K

-2.59%

Ms. Kelly A. Romano

Independent Chairwoman of the Board

8.07K

-23.06%

Dr. Javier San Martin, M.D.

Chief Medical Officer

7.17K

-13.14%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月20日周六

持股股东

股东类型

持股股东

占比

Perceptive Advisors LLC

13.70%

Simplify Asset Management Inc

7.57%

Baselake Management, LLC

5.63%

Nemean Asset Management, LLC

4.09%

The Vanguard Group, Inc.

3.90%

其他

65.11%

持股股东

占比

Perceptive Advisors LLC

13.70%

Simplify Asset Management Inc

7.57%

Baselake Management, LLC

5.63%

Nemean Asset Management, LLC

4.09%

The Vanguard Group, Inc.

3.90%

其他

65.11%

股东类型

持股股东

占比

Private Equity

13.96%

Investment Advisor

13.62%

Corporation

9.73%

Hedge Fund

4.09%

Venture Capital

3.79%

Individual Investor

3.63%

Investment Advisor/Hedge Fund

2.20%

Family Office

0.98%

Research Firm

0.83%

其他

47.17%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

111

1.69M

59.67%

+2.61K

2025Q3

123

1.85M

67.42%

-29.98K

2025Q2

137

1.88M

68.23%

-792.00

2025Q1

169

1.88M

71.62%

-912.05K

2024Q4

181

1.93M

77.37%

-30.53K

2024Q3

198

1.93M

80.55%

-610.31K

2024Q2

215

2.54M

81.59%

+49.57K

2024Q1

233

2.49M

97.31%

-1.23M

2023Q4

240

2.51M

94.17%

+48.15K

2023Q3

248

2.46M

95.12%

-62.03K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Perceptive Advisors LLC

540.30K

13.7%

Jun 30, 2025

Simplify Asset Management Inc

149.28K

3.79%

Jun 30, 2025

Nemean Asset Management, LLC

199.47K

5.06%

+199.47K

Apr 14, 2025

The Vanguard Group, Inc.

153.79K

3.9%

Jun 30, 2025

Tang Capital Management, LLC

60.00K

1.52%

Jun 30, 2025

Renaissance Technologies LLC

24.10K

0.61%

+2.20K

+10.05%

Jun 30, 2025

Acadian Asset Management LLC

40.55K

1.03%

-2.31K

-5.38%

Jun 30, 2025

Pathstone

37.22K

0.94%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

37.24K

0.94%

-7.40K

-16.58%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Propel Opportunities ETF

0.92%

iShares Neuroscience and Healthcare ETF

Avantis US Small Cap Equity ETF

iShares US Small-Cap Equity Factor ETF

iShares Micro-Cap ETF

Dimensional US Core Equity 1 ETF

DFA Dimensional US Sustainability Core 1 ETF

Simplify Propel Opportunities ETF

占比0.92%

iShares Neuroscience and Healthcare ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

iShares US Small-Cap Equity Factor ETF

占比0%

iShares Micro-Cap ETF

占比0%

Dimensional US Core Equity 1 ETF

占比0%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Sep 11, 2025

Merger

10→1

公告日期

类型

比率

Sep 11, 2025

Merger

10→1

常见问题

Athira Pharma Inc的前五大股东是谁？



Athira Pharma Inc 的前五大股东如下：
Perceptive Advisors LLC持有股份：540.30K，占总股份比例：13.70%。
Simplify Asset Management Inc持有股份：149.28K，占总股份比例：3.79%。
Nemean Asset Management, LLC持有股份：199.47K，占总股份比例：5.06%。
The Vanguard Group, Inc.持有股份：153.79K，占总股份比例：3.90%。
Tang Capital Management, LLC持有股份：60.00K，占总股份比例：1.52%。